Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database

Mylène Annonay, MD a, Lisa Gauquelin, MD b,c, Romain Geiss, MD d, Mony Ung, MD e, Laurence Cristol-Dalstein, MD f, Marie-Ange Mouret-Reynier, MD PhD g, Anthony Goncalves, MD PhD h, Sophie Abadie-Lacourtoisie, MD i, Eric Francois, MD j, Christophe Perrin, MD k, Johan Le Fel, MD l, Véronique Lorigs, MD m, Véronique Servent, MD n, Lionel Uwer, MD o, Christelle Jouannaud, MD p, Marianne Leheurtier, MD q, Florence Joly, MD PhD r, Loic Campion, MD s, Coralie Courtinard, MPH t, Olivier Villacroux, MD u, Thierry Petit, MD PhD v, Pierre Soubeyran, MD a, Catherine Terret, MD w, Carine Bellera, PhD b,c, Etienne Brain, MD PhD d, Suzette Delaloge, MD MPH x, *

* Corresponding author. Department of Medical Oncology, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94805, Villejuif, France.
E-mail address: suzette.delaloge@gustaveroussy.fr (S. Delaloge).

**Corresponding author.** Department of Medical Cancer medicine, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94805, Villejuif, France.

Article info
Article history:
Received 4 July 2021
Received in revised form
6 September 2021
Accepted 18 September 2021
Available online 1 October 2021

Abstract

Background: Treatment and outcomes of patients with HER2-positive (HER2+) metastatic breast cancer (MBC) have dramatically improved over the past 20 years. This work evaluated treatment patterns and outcomes according to age.

Methods: Women who initiated a treatment for HER2+ MBC between 2008 and 2016 in one of the 18 French comprehensive centers part of the ESME program were included. Objectives were the description of first-line treatment patterns, overall survival (OS), first-line progression-free survival (PFS), and prognostic factors among patients aged 70 years or more (70+), or less than 70 (<70).
Results: Of 4045 women diagnosed with an HER2+ MBC, 814 (20%) were 70+. Standard first-line treatment (chemotherapy combined with an anti-HER2 therapy) was prescribed in 65% of 70+ versus 89% of <70 patients (p < 0.01). Median OS was 49.2 (95% CI, 47.1–52.4), 35.3 (95% CI, 31.5–37.0) and 54.2 months (95% CI, 50.8–55.7) in the whole population, in patients 70+ and <70, respectively. Corresponding median PFS were 12.8 (95% CI, 12.3–13.3), 11.1 (95% CI, 10.0–12.3) and 13.2 months (95% CI, 12.7–13.9), respectively. In 70+ women, initiation of non-standard first-line treatment had an independent detrimental time-varying effect on both OS and PFS (HR on OS at 1 year: chemotherapy without anti-HER2 2.79 [95% CI: 2.05–3.79]; endocrine therapy and/or anti-HER2 1.96 [95% CI: 1.43–2.68]).

Conclusions: In this large retrospective real-life database, older women with HER2+ MBC received standard first-line treatment less frequently than younger ones. This was independently associated with a worse outcome, but confounding factors and usual selection biases cannot be ruled out.

© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Aging is the most important risk factor for developing cancer. Breast cancer (BC) is not an exception to the rule, with a median age of 62 years at diagnosis, 40–50% being diagnosed at age 70 or older in western countries [1]. Human epidermal growth factor receptor 2-positive (HER2+) BC, defined by an overexpression of HER2 or a HER2 gene amplification accounts for 20% of metastatic BC (MBC) and 10% of older patients with cancer [2,3]. Since the early 2000s, many anti-HER2 therapies have revolutionized the prognosis of HER2+ MBC patients, from trastuzumab added to first-line chemotherapy [4] to the more recent dual anti-HER2 blockade adding a second antibody, pertuzumab, increasing further overall survival (OS) by 16 months [5]. Both lapatinib and T-DM1 contributed also to the global improvement of HER2+ MBC prognosis [6–8], and the list of anti-HER2 treatments has been updated very recently with tucatinib and new antibody-drug conjugates as DS-8201 [9,10]. Most of these strategies show a good safety profile, although data available are sparse in older patients [11–13]. Indeed, older patients remain underrepresented in clinical trials. Moreover, when enrolled, they do not reflect those seen in routine oncology practice because of restrictive eligibility criteria [14,15]. Older patients also show poorer outcome compared with younger ones, even when adjusted for classical prognostic tumours characteristics [16].

The American Society of Clinical Oncology supports high-quality observational studies as complementary to randomized controlled trials (RCTs) to improve evidence-based practice [17]. Unveiling information absent in highly selected settings as most RCTs, observational data can help generating hypotheses, especially for populations underrepresented in RCTs, such as older patients. Observational data however require cautious interpretation to address the usual confounding factors and lack of control [18]. Large observational real-life datasets, such as the longitudinal Epidemiology Strategy and Medical Economics (ESME) MBC database, represent an opportunity to investigate treatment real-life patterns and outcomes for distinct subgroups of MBC patients. RCT data on anti-HER2 treatments and outcome in older patients with MBC being limited, objectives were to describe treatment patterns, overall survival (OS) and first-line progression-free survival (PFS) in women with HER2+ MBC aged 70 and older (70+), as compared to younger ones (<70) over the last decade, based on the ESME real-life database [19].

2. Patients and methods

2.1. Overall study design

The French ESME MBC database (NCT03275311) is a national multicenter observational program. It collects real world data from all consecutive MBC patients aged ≥18 years who initiated their care at the time of MBC diagnosis, in the network of 18 French comprehensive cancer centers, starting from 2008 [2,20]. Patients referred “secondary” after they have initiated their first-line treatment elsewhere are not eligible for the cohort. Data are updated annually and include latest patients’ and tumours’ characteristics, outcomes and treatment patterns. ESME does not collect data on toxicity or patient reported outcomes.

The present analysis was approved by an independent ethics committee (Comité De Protection Des Personnes Sud-Est II-2015-79). No formal dedicated informed consent was required but all patients had approved the re-use of their electronically recorded data. In compliance with French regulations, the ESME MBC database was authorized by the French data protection authority (Registration ID 1704113 and authorization N’DE-2013-117). Moreover, in compliance with the applicable European regulations, a complementary authorization was obtained on 14-Oct-2019 regarding the ESME research Data Warehouse.

2.2. Patients selection

For the present study, all women in the ESME database who had a metastatic breast cancer classified as “HER2-positive” (HER2+) were selected. As described before, HER2 and HR status are derived from existing results about metastatic tissue sampling where available, or, if not available, from last sampling on early disease [8]. HER2+ means that the latest available sample of the tumor has a HER2 immunohistochemical score (IHC) 3+, or 2+ with a positive chromogenic/fluorescence in situ hybridization (CISH/FISH), whether hormone receptor positive or negative.

2.3. Definitions and endpoints

Tumours were defined as hormone receptors (HR) positive if ER and/or PgR expression was >10% by IHC. Metastases-free interval (MFI) was defined as the time between initial diagnosis and metastatic relapse, and categorized in three groups (<6, 7–24, >24 months). First-line treatment was categorized as anti-HER2 therapy-based [combined with either chemotherapy (defined as “standard” 1st line treatment), or endocrine therapy, or their combination] or not anti-HER2 therapy-based (i.e. chemotherapy alone or endocrine therapy alone or their combination). The size of the treating centre was categorized according to the number of patients included in the ESME cohort (<700, 700–1399, ≥1400 patients). OS and PFS were defined as the delay between the date of diagnosis of MBC and the date of death (any cause), or the date of disease progression or death (any cause), respectively.
2.4. Statistical analyses

Qualitative variables were described using frequency, percentage and 95% confidence interval (95%CI) (binomial law). They were compared using a Chi² test or a Fisher’s exact test whenever appropriate. Quantitative variables were described using mean and standard deviations if the normality assumption was satisfied; otherwise non-parametric statistics (median, range, quartiles) were reported and compared using non-parametric Wilcoxon tests. Median follow up was estimated using the reverse Kaplan–Meier estimator [21]. Survival times were described using the Kaplan–Meier method and the median survival times and rates with 95% CI were reported.

Regarding prognostic factors for time-to-event endpoints, independent analyses were carried out in the whole population, in the older one (>70+) and in the younger one (<70). Univariate analyses were first performed using Cox’s proportional hazards (PH) models. Variables significant at the 15%-level were fitted in multivariable models with final significance level set at 5%. The strength of the association was estimated using the hazard ratio (HR) reported with 95%CI. Prognostic factors investigated included: age at diagnosis of metastasis (<70 vs >70 for the analysis in the whole population, continuously for the analysis per age group); tumour hormonal receptor status (ER+ and/or PgR+ vs ER- and PgR-); number of metastatic sites (1, 2, 3 or more) at diagnosis of metastasis; visceral metastases at diagnosis of metastasis; de novo metastatic disease; MFI; choice of first-line treatment; size of the treating centre. Baseline performance status (PS) and body mass index (BMI) were not considered because of missing data exceeding 30%. The hypothesis of proportional hazards was assessed. When this assumption was not verified, variables were included in the Cox model using an interaction with time in order to provide unbiased estimations.

All analyses were conducted with SAS software, version 9.4 (SAS institute Inc., Cary NC, USA).

3. Results

3.1. Patients, tumours and first-line treatments characteristics

Of the 22463 patients available in the ESME MBC database and diagnosed between January 2008 and December 2016, 4045 (18.0%) had an HER2+ MBC, 814 of them (20.1%) being >70+ (Fig. 1). Median age in the whole population, in the >70+ and <70 groups was 57 (range: [20–93]), 77 (range: [70–93]) and 53 (range: [20–69]) years, respectively. Among older patients, 524 (64.4%) were >70 and 274 (33.7%) 80–89, and 16 (2%) 90 years old and over. Additional patients and tumours’ characteristics are reported in Table 1. Compared with women <70, older women had more often ER+ and/or PgR+ disease (68.8% versus 63.0%, p = 0.01).

First line treatments received are described in Table 2. The distribution of standard first-line treatment (chemotherapy combined with an anti-HER2 treatment) was different according to the age group (p < 0.01). Younger women received standard first-line treatment more often than older women (89.1% vs 65.0%). They also overall received anti-HER2 therapy (alone or in combination) more often than women aged >70+ (92.3% vs 76.5%).

3.2. Overall survival and first-line progression free survival by age category

With a median follow up of 53.4 months (95% CI, 50.9–55.4), 2049 patients (50.7%) were alive at data cut off. Median overall survival was 49.2 months (95% CI, 47.1–52.4) in the whole cohort; 35.3 months (95% CI, 31.5–37.0) and 54.2 months (95% CI, 50.8–55.7) among women aged >70+ and <70, respectively (Fig. 2). Corresponding results for PFS were 12.8 (95% CI, 12.3–13.3), 11.1 (95% CI, 10.0–12.3) and 13.2 months (95% CI, 12.7–13.9), respectively (see Fig. 3).

3.3. Multivariate analyses

Table 3 describes the multivariate analysis of factors associated with OS in the different groups of patients. Within the whole cohort, this analysis retrieved classical prognostic factors associated with shorter OS, including increasing age (HR = 1.55; 95% CI, 1.38–1.73), higher number of metastatic sites (for modality 3 or more sites, HR = 2.95; 95% CI, 1.85–2.39), 6–24 months MFI (HR = 2.58; 95% CI, 2.25–2.95), presence of visceral metastases (HR = 2.67 at one year; 95% CI, 2.10–3.38). Longer OS was associated with positive hormone receptors (HR = 0.63 at one year; 95% CI, 0.56–0.71) and centers with a higher patient load (for 1400 or
Hormone receptors’ effect decreased over time, disappearing at 5 years. On the opposite, the detrimental effect of visceral involvement increased over time. Finally, as compared to standard first-line treatment (chemotherapy combined with anti-HER2 therapy), non-standard treatments were associated with an increased risk of death during the first years.

In the 70+ group, same trends were reported for most variables, although with no time-varying effect for hormone receptor status (HR = 0.77; 95% CI, 0.62—0.95) and no impact of the size of the treating centre. Increased age was associated with shorter OS (HR = 1.05; 95% CI, 1.03—1.07).

Table 1
Characteristics of the patients.

| Population (N) | All (4045) | 70+ (814) | <70 (3231) |
|----------------|------------|-----------|------------|
| **Patients characteristics** |            |           |            |
| Median age at diagnosis (years) (Q1;Q3) | 57 (47–67) | 77 (73–82) | 53 (45–60) |
| PS at MBC diagnosis |            |           |            |
| 0 | 723 (17.9%) | 67 (8.2%) | 656 (20.3) |
| 1 | 607 (15.0%) | 123 (15.1%) | 484 (15.0%) |
| 2 | 175 (4.3%) | 53 (6.5%) | 122 (3.8%) |
| 3 | 66 (1.6%) | 18 (2.2%) | 48 (1.5%) |
| 4 | 10 (0.2%) | 3 (0.4%) | 7 (0.2%) |
| Missing | 2464 (60.9%) | 550 (67.6%) | 1914 (59.2%) |
| BMI, median (Q1;Q3) | 24.7 (21.6; 28.7) | 25.2 (22.2; 29.3) | 24.6 (21.5; 28.6) |
| **Histological type (primary tumor)** |           |           |            |
| IDC | 3319 (82.1%) | 633 (77.8%) | 2686 (83.1%) |
| ILC | 226 (5.6%) | 69 (8.5%) | 157 (4.9%) |
| Breast cancer origin |           |           |            |
| 0 | 17 (0.4%) | 2 (0.2%) | 15 (0.5%) |
| Other | 399 (9.9%) | 89 (10.9%) | 310 (9.6%) |
| Missing | 48 (1.2%) | 12 (1.5%) | 36 (1.1%) |
| **Histological grade (primary tumor)** |           |           |            |
| Grade I | 179 (4.4%) | 49 (6.0%) | 130 (4.0%) |
| Grade II | 1629 (40.3%) | 328 (40.3%) | 1301 (40.3%) |
| Grade III | 1589 (39.3%) | 288 (35.4%) | 1301 (40.3%) |
| Missing | 648 (16.0%) | 149 (18.3%) | 499 (15.5%) |
| **ER/PgR status** |           |           |            |
| ER- and PgR- | 2594 (64.1%) | 560 (68.8%) | 2034 (63.0%) |
| ER+ and/or PgR+ (>10%) | 1414 (35.0%) | 247 (30.3%) | 1167 (36.1%) |
| Undetermined | 37 (0.9%) | 7 (0.9%) | 30 (0.9%) |
| **MFI (months)** |           |           |            |
| ≤ 6 | 1626 (40.2%) | 311 (38.2%) | 1315 (40.7%) |
| > 24 | 1850 (45.7%) | 398 (48.9%) | 1452 (44.9%) |
| Missing | 7 (0.2%) | 1 (0.1%) | 6 (0.2%) |
| **Number of metastatic sites at diagnosis** |           |           |            |
| 1 | 2099 (51.9%) | 429 (52.7%) | 1670 (51.7%) |
| 2 | 1045 (25.8%) | 211 (25.9%) | 834 (25.8%) |
| ≥ 3 | 866 (21.4%) | 170 (20.9%) | 696 (21.5%) |
| Missing | 35 (0.9%) | 4 (0.5%) | 31 (1.0%) |
| **Presence of visceral disease at diagnosis** |           |           |            |
| Yes | 2606 (64.4%) | 510 (62.7%) | 2096 (64.9%) |
| No | 1404 (34.7%) | 300 (36.9%) | 1104 (34.2%) |
| Missing | 35 (0.9%) | 4 (0.5%) | 31 (1.0%) |
| **Brain metastases at diagnosis** |           |           |            |
| Yes | 591 (14.6%) | 92 (11.3%) | 499 (15.4%) |
| No | 3454 (85.4%) | 722 (88.7%) | 2732 (84.6%) |

ILC: Invasive lobular carcinoma; FISH: Fluorescence in situ hybridization; CISH: Chromogenic in situ hybridization; ER: Estrogen receptor; PgR: Progesterone receptor; MBC: Metastatic breast cancer; MFI: Metastasis free interval; NA: Not applicable.

Table 2
First-line treatment characteristics.

| First-line treatment | All (N = 4045) | Women 70+ (N = 814) | Women <70 (N = 3231) |
|----------------------|----------------|---------------------|---------------------|
| Anti-HER2 therapy + chemotherapy | 3409 (84.3%) | 529 (65.0%) | 2880 (89.1%) |
| Chemotherapy without anti Her2 | 222 (5.5%) | 68 (8.4%) | 154 (4.8%) |
| Anti-HER2 + endocrine therapy | 113 (2.8%) | 63 (7.7%) | 50 (1.5%) |
| Anti-HER2 therapy alone | 85 (2.1%) | 31 (3.8%) | 54 (1.7%) |
| Endocrine therapy alone | 117 (2.9%) | 79 (9.7%) | 38 (1.2%) |
| Missing | 99 (2.4%) | 44 (5.4%) | 55 (1.7%) |
| Center size (number of patients/site) |           |           |            |
| ≤ 700 | 202 (5.0%) | 31 (3.8%) | 171 (5.3%) |
| 700—1399 | 2865 (70.8%) | 599 (73.6%) | 2266 (70.1%) |
| ≥ 1400 | 978 (24.2%) | 184 (22.6%) | 794 (24.6%) |
Results on the <70 group were similar to those found in the whole population. Table 4 describes the multivariate analysis for PFS. In the whole population, independent prognostic factors for shorter PFS were similar to those for OS. As compared to chemotherapy with anti-HER2, both chemotherapy without anti-HER2 and treatment without chemotherapy/anti-HER2 were associated with an increased risk of progression over the first 3 years: HR = 1.93 [95% CI: 1.67–2.23] and HR = 1.75 [95% CI: 1.51–2.03] at 1 year, respectively.

In the 70+ group, same trends were observed for most variables. No association was found with the size of the treating centre. Older age was associated with shorter PFS (HR = 1.03; 95% CI, 1.01–1.04). Compared with chemotherapy + anti-HER2 therapy, chemotherapy alone had a deleterious non time-dependent effect on PFS (HR = 1.54 [95% CI: 1.18–2.02]), while treatment without chemotherapy had no real impact (HR = 0.86 [95% CI: 0.70–1.05]).

4. Discussion

To our knowledge, this report describes the largest real-life cohort of women aged 70 or older with HER2+ MBC treated with recent anti-HER2 therapies. Older patients being largely under-represented in clinical trials, including those investigating anti-HER2 therapies, very few data are available for this subpopulation [19,22]. For example, CLEOPATRA included only 126 patients aged 65 years or older, with a median age of 69 years [13]. Moreover, of 808 patients enrolled, only 19 were aged 75 or older. With striking numbers, we report on 814 women 70 years or older, with a median age of 77 years, more representative of daily clinical practice.
In this large retrospective cohort, we observed that only 65% of patients 70+ received anti-HER2 treatment with chemotherapy, defined as standard first-line treatment, compared with 89.1% of those <70 (global statistical test of first-line treatment distribution, p < 0.01). Older patients may have impaired cardiac function, limiting the prescription of anti-HER2 treatments and chemotherapy combinations. Increased toxicity is also feared, even in the absence of such condition [23,24]. Our results suggest that these differences in treatment choice may have an impact on the outcome of older patients. Indeed, both PFS and OS in the 70+ group were significantly lower than in those patients <70 with median survival of 11.1 months (95% CI, 10.0–12.3) and 35.3 months (95% CI, 31.5–37.0) versus 13.2 months (95% CI, 12.7–13.9) and 49.2 months (95% CI, 47.1–52.4), respectively. After adjustment for tumour characteristics, this effect of different treatment choices on OS seemed to be present early, at 12 and 36 months, declining later at 60 months. Of note, 11.5% of women 70+ received anti-HER2 alone or with endocrine therapy vs 3.2% in patients <70, stressing the high interest for chemo-free combinations or combinations with milder chemotherapy in the older population, as supported by the recommendations by the Société Internationale d’Oncogériatrie (SIOG) [19]. Moreover, although anti-HER2 alone or with endocrine therapy had a detrimental effect on OS compared with standard treatment, outcome was still better than chemotherapy alone.

As previously described, misestimating women’s capacity and remaining life expectancy may have contributed to undertreatment, resulting in worse outcomes in older patients. However, some older patients with cancer have many competing risks of death due to multimorbidities. These should be carefully assessed before treatment decision, especially because older persons may develop more often important side effects, related to changes in pharmacodynamic parameters, polypharmacy and underlying frailty [25]. As advocated by SIOG, treatment of BC in older patients should not be based on chronological age alone [26]. Screening for

Table 3
Prognostic factors of overall survival in metastatic breast cancer patients in the ESME real-life database according to age.

| Age (continuous variable) | All women | >70 | <70 |
|---------------------------|-----------|-----|-----|
| Number of metastatic sites at metastatic diagnosis (reference: 1 site) | NA | 1.05 [1.03; 1.07] | <0.01 |
| 2 sites | 1.32 [1.18; 1.49] | 1.29 [1.01; 1.65] | 1.34 [1.17; 1.53] |
| 3 sites or more | 2.10 [1.85; 2.39] | <0.01 | 1.87 [1.43; 2.45] |
| Median survival of 11.1 months (95% CI, 10.0 | NA | 1.01 [1.00; 1.01] | 0.05 |

| Age (reference: < 70) | >70 | <70 |
|-----------------------|-----|-----|
| Median survival of 11.1 months (95% CI, 10.0 | NA | 1.01 [1.00; 1.01] | 0.05 |

| Center size (number of patients/site) (reference: less than 700 patients) | 700 to 1399 patients | >1400 patients |
|---------------------------|---------------------|----------------|
| 700 to 1399 patients | 0.87 [0.71; 1.06] | NS |
| >1400 patients | 0.63 [0.50; 0.78] | NS |

HR: Hazard ratio.
ER: Estrogen receptor.
PGR: Progesterone receptor.
MFI: Metastasis free interval.
NS: Not significant.
NA: Not applicable.

| MFI (months) (reference: < 6 months) | 0.05 | <0.01 |
|-------------------------------------|------|-------|
| 6–24 months | 2.58 [2.25; 2.95] | 1.42 [1.05; 1.92] | 3.06 [2.62; 3.58] |
| 24 months and more | 1.37 [1.24; 1.52] | <0.01 | 1.01 [0.82; 1.26] | 1.52 [1.35; 1.71] |
frailty, and delving further in the general health status, with a developed and personalized geriatric assessment when frailty is suggested, has become a mandatory and helpful strategy.

Although combination with chemotherapy has been established as the standard use [27,28], older patients are at increased risk of treatment-induced toxicity and require important strategy adjustments [19]. Even in fit ones who may be treated as younger ones, there should be no decreased attention regarding potential toxicity. For those who are frail or unfit, less toxic schedules and combinations are recommended. For example, the EORTC conducted an open label randomized phase II trial in first line HER2+ MBC in older and frail patients [28]. Seventeen percent of patients had a G8 \leq 14, suggesting potential frailty. Patients were randomized between dual anti-HER2 blockade (pertuzumab + trastuzumab) alone or with metronomic cyclophosphamide, reaching a median PFS of 5.6 months (95% CI 30.2–60.7) and 12.7 months (6.7–24.8), respectively, providing an attractive alternative to the standard combination of dual blockade with taxanes. The TANDEM trial also investigated successfully trastuzumab with endocrine therapy in luminal HER2+ post-menopausal women with MBC [29]. Most recently, the PERTAIN trial, with a median PFS of 27 months in the group of patients who received aromatase inhibitors with

### Table 4
Prognostic factors of progression-free survival in metastatic breast cancer patients in the ESME real-life database according to age.

|                                    | All women | 70+ | <70 |
|------------------------------------|-----------|-----|-----|
| Age (reference: < 70)              | HR        | 95% CI | p   | HR        | 95% CI | p   | HR        | 95% CI | p   |
| <70                                | NS        | NA   | NA  | NS        | NA  | NA  | NS        | NA  | NA  |
| Age (continuous variable)          | NA        | 1.03 [1.01; 1.04] | <0.01 | NA        | NA  | NA  | NA        | NA  | NA  |
| Number of metastatic sites at metastatic diagnosis (reference: 1 site) | NA  | <0.01 | <0.01 | <0.01 |
| 2 sites                            | 1.20 [1.10; 1.31] | 1.21 [1.00; 1.48] | 1.29 [1.16; 1.42] |
| 3 sites or more                    | 1.45 [1.31; 1.61] | 1.55 [1.24; 1.94] | 1.72 [1.54; 1.93] |
| Visceral metastatic disease (reference: none) (*) | NA  | <0.01 | <0.01 | <0.01 |
| If no time; varying effect: Global HR | NA  | 1.35 [1.12; 1.63] | NA  | NA  | NA  |
| Time; varying effect:             | NA  | NA  | NA  | NA  | NA  | NA  |
| Estimated HR at 1 year            | 1.47 [1.22; 1.76] | NA  | 1.59 [1.30; 1.95] |
| Estimated HR at 3 years           | 1.71 [1.43; 2.05] | NA  | 2.02 [1.65; 2.47] |
| Estimated HR at 5 years           | 2.00 [1.67; 2.40] | NA  | 2.56 [2.09; 3.13] |
| ER/PgR status (reference: both ER; and PgR:) | NA  | <0.01 | NA  | NA  | NA  | <0.01 |
| If no time; varying effect, estimated average HR | NA  | NA  | NA  | NA  | NA  | NA  |
| Positive ER and/or PgR            | NA        | NA  | NA  | NA  | NA  | NA  |
| Undetermined ER/PgR status        | NA        | NA  | NA  | NA  | NA  | NA  |
| If time; varying effect, estimated HR at 1 year | 0.92 [0.85; 0.99] | 0.87 [0.80; 0.95] |
| Positive ER and/or PgR            | 0.86 [0.58; 1.26] | 0.78 [0.50; 1.22] |
| Undetermined ER/PgR status        | 1.13 [1.05; 1.22] | 1.08 [1.00; 1.18] |
| If time; varying effect, estimated HR at 3 years | 1.05 [0.71; 1.55] | 0.97 [0.62; 1.51] |
| Positive ER and/or PgR            | 1.39 [1.28; 1.50] | 1.35 [1.24; 1.46] |
| Undetermined ER/PgR status        | 1.29 [0.88; 1.90] | 1.20 [0.77; 1.87] |
| First-line treatment (vs chemotherapy + anti; HER2 therapy ± endocrine therapy) | NA  | <0.01 | 1.54 [1.18; 2.02] | <0.01 | NA  | NA  | <0.01 |
| If no time-varying effect: Estimated average HR chemotherapy without anti-HER2 therapy (+endocrine therapy) | NA  | NA  | NA  | NA  | NA  | NA  |
| anti-HER2 therapy alone or endocrine therapy alone or both | NA  | NA  | NA  | NA  | NA  | NA  |
| At 1 year | chemotherapy without anti-HER2 therapy (+endocrine therapy) | 1.93 [1.67; 2.23] | 1.68 [1.41; 2.00] |
| anti-HER2 therapy alone or endocrine therapy alone or both | 1.75 [1.51; 2.03] | 0.64 [0.49; 0.84] |
| At 3 years | chemotherapy without anti-HER2 therapy (+endocrine therapy) | 1.17 [1.00; 1.34] | 1.29 [1.08; 1.54] |
| anti-HER2 therapy alone or endocrine therapy alone or both | 1.06 [0.92; 1.23] | 0.49 [0.38; 0.64] |
| At 5 years | chemotherapy without anti; HER2 therapy (+endocrine therapy) | 0.71 [0.62; 0.83] | 0.99 [0.83; 1.18] |
| anti-HER2 therapy alone or endocrine therapy alone or both | 0.65 [0.56; 0.75] | 0.38 [0.29; 0.49] |
| MFI (months) (reference: < 6 months) | 2.10 [1.87; 2.35] | 1.71 [1.33; 2.23] | 2.42 [2.14; 2.74] | <0.01 |
| 6–24 months | 24 months and more | 1.46 [1.35; 1.58] | 1.09 [0.91; 1.29] | 1.43 [1.31; 1.56] | <0.01 |
| Center size (number of patients/site) (reference: < 700 patients) | 0.83 [0.71; 0.98] | 0.80 [0.68; 0.95] | 0.68 [0.57; 0.82] | <0.01 |
| 700 to 1399 patients | 1400 patients and more | 0.74 [0.62; 0.88] | NA  | NS  | NS  | NA  |
| HR: Hazard ratio.                  |           |      |      |      |      |      |      |
| ER: Estrogen receptor.             |           |      |      |      |      |      |      |
| PgR: Progesterone receptor.        |           |      |      |      |      |      |      |
| MFI: Metastasis free interval.     |           |      |      |      |      |      |      |
| NS: Not significant.               |           |      |      |      |      |      |      |
| NA: Not applicable.                |           |      |      |      |      |      |      |

95% CI: 95% confidence interval.

HR: Hazard ratio.

*References*

[19] The Breast 60 (2021) 138–146
pertuzumab and trastuzumab, highlights that some patients may benefit from this combination, without chemotherapy [30].

The major strength of our work is the size of the cohort, which includes all HER2+ MBC 70+ with no age limitations nor selection based on multimorbidities, making it more representative of daily clinical practice.

However, our study has also major limitations. First, due to missing data, we could not assess relative BC survival to take into account competing risks for death. Furthermore, older patients treated in comprehensive cancer centers may not be representative of all patients, limiting extrapolation to other institutions, because they tend to have less comorbidities and a higher socio economic level than those referred to smaller local clinics and hospitals [31].

Other important limitations are due to the retrospective nature of our cohort. Indicators of frailty like the screening tool G8, PS, comorbidities or geriatric assessment, which provide prognostic information in older populations with or without cancer, were missing. Assessment of treatment safety was not available. We also could not eliminate confounding factors like patient’s choice who may have influenced treatment decision. Although it would be of interest, the number of patients aged >70 years did not allow subgroup analyses by age groups.

Finally, finding that the large size of the treating centre (evaluated though the number of patients accrued in the cohort, which is fully correlated to the total patients’ load of the center) had a protective effect in the whole or younger population but not in the older one is counterintuitive. Larger institutions have generally higher resources to contract geriatricians to help tailoring treatments in older patients, unless skewed or selected patients recruitments create uneaven access to these. This requires further exploration and may reflect a different patient profile within larger centers. Of note, secondary referrals are much more frequent in bigger centers, but such patients are excluded from ESME and this would not affect our results based on first-line treatments.

5. Conclusion

In this real world cohort, only 65% of women 70+ received standard first-line treatment defined as chemotherapy with anti-HER2 therapy, with or without endocrine therapy. Older women were less likely to receive standard therapy compared with their younger counterparts. These treatment differences were associated with worse PFS and OS, although a causal relationship cannot strictly be demonstrated. Given the lack of information on geriatric assessment (e.g. general health status, functional status, comorbidity, etc.), confounding factors and usual selection biases cannot be ruled out. These results stress the importance to study older populations with specific approaches, not based on the usual transfer of those developed in younger ones, in order to avoid under and overtreatments.

Funding

The ESME MBC database receives financial support from an Industrial consortium (Roche, Pfizer, AstraZeneca, MSD, Eisai and Daiichi Sankyo). Data collection, analysis and publication are managed entirely by UNICANCER independently of the industrial consortium.

Acknowledgements

We thank the 18 French Comprehensive Cancer Centers (FCCC); I. Curie, Paris/Saint-Cloud, G. Roussy, Villejuif, I. Cancéropôle de l’Ouest, Angers/Nantes, C. F. Baclesse, Caen, ICM Montpellier, C. L. Béard, Lyon, C. G-F Leclerc, Dijon, C. H. Becquereul, Rouen; I. C. Regaud, Toulouse; C. A. Lacassagne, Nice; Institut de Cancérologie de Lorraine, Nancy; C. E. Marquis, Rennes; I. Paoli-Calmettes, Marseille; C. Perrin, Clermont Ferrand; I. Bergonié, Bordeaux; C. P. Strauss, Strasbourg; I. J. Godinot, Reims; C. O. Lambret, Lille.

References

[1] Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019;195(8):1941–53. 144.
[2] Deluche E, Antoine A, Bachelot T, Lardy-ClouxD A, Dierss V, Brain E, et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016. Eur J Canc avr 2020;129: 60–70.
[3] Jenkins EO, Deal AM, Anders CK, Prat A, Perou CM, Carey LA, et al. Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. Oncol oct 2014;19(10):1076–83.
[4] Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 15 mars 2001;344(14):783–92.
[5] Swain SM, Miles D, Kim S-R, Im Y-H, Im S-A, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol avr 2020;21(4):519–30.
[6] Dierss V, Miles D, Verma S, Pregam M, Weislauf M, Baselga J, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival from a randomised, open-label, phase 3 trial. Lancet Oncol juin 2017;18(6):732–42.
[7] Kroop BE, Kim S-B, Gronli Å, Besse T, A LaRussa PM, Ferrero J-M, Smitt M, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol avr 2016;17(4):429–39.
[8] Gobbin E, Ezzalzafni M, Dierss V, Bachelot T, Brain E, Debled M, et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort, Eur J Canc avr 2018;56:17–24.
[9] Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 15 févr 2020;382(7):610–21.
[10] Murthy RK, Loi S, Okines A, Papamosta E, Hamilton E, Hurvitz SA, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 15 févr 2020;382(7):597–609.
[11] Daniels B, Kiely BE, Tang M, Tervonen H, Pearson S-A. Trastuzumab use in breast cancer that overexpresses HER2. N Engl J Med. 15 mars 2001;344(11):788–99.
[12] Miles D, Baselga J, Amadori D, Sunpaweravong P, Semiglazov V, Knott A, et al. Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registrHER observational study. Breast Cancer Res Treat oct 2012;135(3):875–83.
[13] Modis S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 15 févr 2020;382(7):610–21.
[14] Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 15 nov 2004;22(22):4626–31.
[15] Freedman RA, Foster JC, Seisler DK, Lafay JM, Muss BH, Cohen HJ, et al. Accrual of older patients with breast cancer to all-systmatics therapy trials over time: protocol a151527. J Clin Oncol nov 2017;35(4):421–21.
[16] Smith BD, Jiang J, McLaughlin SS, Hurria A, Smith GL, Giordano SH, et al. Improvement in breast cancer outcomes over time: are older women missing out? J Clin Oncol 10 déc 2011;29(35):4647–53.
[17] Vivianathan K, Levit LA, Raghavan D, Hudis CA, Wong S, Dueck A, et al. Untapped potential of observational research to inform clinical decision making: American society of clinical oncology research statement. J Clin Oncol 1 juin 2011;29(16):1845–54.
[18] Collins R, Bowman L, Landray M, Peto R. The magic of randomization versus the myth of real-world evidence. N Engl J Med févr 2020;382(7):674–8. 382.
[19] Brain E, Cailler P, de Glas N, Biganzoli L, Cheng K, Lago LD, et al. HER2-targeted treatment for older patients with breast cancer: an expert position paper from the International Society of Geriatric Oncology. J Geriatr Onc avr 2019;10(6):1003–13.
[20] Pérol D, Rohain M, Arveux P, Mathoulin-PierREL S, Chamayre E, Aisslein B, et al. The ongoing French metastatic breast cancer (MBC) cohort: the
example-based methodology of the Epidemiological Strategy and Medical Economics (ESME). BMJ Open 21 févr 2019;9(2):e023568.

[21] Schenper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. août 1996;17(4):343–6.

[22] Evans N. Real-world outcomes in elderly patients with HER2-positive advanced breast cancer. In: Presented at: 2020 ESMO Asia 2020 virtual meeting; novembre 20–22; 2020. Virtual. Abstract #51P.

[23] Chavez-MacGregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 20 nov 2013;31(33):4222–8.

[24] Guarneri V, Lenihan DJ, Valero V, Durand J-B, Breglio K, Hess KR, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 1 sept 2006;24(25):4107–15.

[25] Guthrie B, Payne K, Alderson P, McMurdoo MET, Mercer SW. Adapting clinical guidelines to take account of multimorbidity. BMJ 4 oct 2012;345:e6341.

[26] Biganzoli L, Wildiers H, Okman C, Marotti L, Lobl S, Kunkler I, et al. Management of elderly patients with breast cancer: updated recommendations of the international society of geriatric oncology (SIOG) and European society of breast cancer specialists (EUSOMA). Lancet Oncol avr 2012;13(4):e148–160.

[27] Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol sept 1999;17(9):2639–48.

[28] Wildiers H, Tryfonidis K, Dal Lago L, Vuylsteke P, Curigliano G, Waters S, et al. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/ Breast Cancer Group. Lancet Oncol mars 2018;19(3):321–36.

[29] Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TANDEM study. J Clin Oncol 20 nov 2009;27(31):5529–37.

[30] Arpino G. Final analysis of PERTAIN: a randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of first-line pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer 2020 San Antonio Breast Cancer Symposium. Abstract PD3-02.

[31] Delva F, Marien E, Fonck M, Rainfray M, Demeaux JL, et al. Factors influencing general practitioners in the referral of elderly cancer patients. BMC Cancer 2011;11:5.